MedDataX Logo

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets

NCT ID: NCT00913224

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

1993-04-30

Study Completion Date

1993-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioavailability of Diclofenac Sodium 50 mg enteric-coated tablets.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions

NCT00913887

Inflammation
COMPLETED PHASE1

Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions

NCT00864006

Seizures
COMPLETED PHASE1

Relative Bioavailability Study in Healthy Subjects

NCT00924911

Infections, Bacterial
COMPLETED PHASE1

To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions

NCT00913848

Epilepsy Bipolar Disorder
COMPLETED PHASE1

Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions

NCT00834990

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

Group Type EXPERIMENTAL

Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

Intervention Type DRUG

2

Voltaren 50 mg Tablets (Geigy Pharmaceuticals)

Group Type ACTIVE_COMPARATOR

Voltaren 50 mg Tablets (Geigy Pharmaceuticals)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)

Intervention Type DRUG

Voltaren 50 mg Tablets (Geigy Pharmaceuticals)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Maximum Eligible Age

41 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul D. Larsen, M.D.

Role: PRINCIPAL_INVESTIGATOR

Red River Clinic

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B-03113

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
NCT02117505 COMPLETED PHASE1
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
NCT05263895 COMPLETED PHASE1
Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions
NCT00974012 COMPLETED PHASE1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
NCT05099822 TERMINATED PHASE1
Relative Bioavailability Study
NCT01602887 COMPLETED PHASE1
3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule
NCT02034773 COMPLETED PHASE1
Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg
NCT00647712 COMPLETED PHASE1
Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions
NCT00834639 COMPLETED PHASE1
Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations
NCT04814472 COMPLETED PHASE1
Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532
NCT01388829 COMPLETED PHASE1
Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.
NCT06211283 COMPLETED PHASE1
A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants
NCT06477926 COMPLETED PHASE1
GSK1349572 Relative Bioavailability Study
NCT01098513 COMPLETED PHASE1
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791 RECRUITING PHASE1
Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers
NCT02171052 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
NCT00946790 COMPLETED PHASE1
Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions
NCT00974441 COMPLETED PHASE1
Pharmacokinetics Of Celecoxib Test Formulations
NCT00925106 COMPLETED PHASE1
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
NCT06078202 WITHDRAWN PHASE1
Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers
NCT02182193 COMPLETED PHASE1
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820 COMPLETED PHASE1
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
NCT06691906 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469
NCT01971502 COMPLETED PHASE1
Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet
NCT00950404 COMPLETED PHASE1
A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants
NCT01662661 COMPLETED PHASE1